Graduate Fellows: Publications
Home > Cancer (Oncology) > Education & Training > Hematology Oncology Fellowship > Graduate Fellows: Publications
Print

Education & Training

Graduate Fellows: Publications

Recent Graduates/Current Fellows

  1. Seetharam R, Sood A, Goel S. Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance. Ecancermedicalscience. 2009;3:153. Epub 2009 Sep 24 PMID: 22276017.
  2. Raghupathy R, Billett HH. Promising Therapies in Sickle Cell Disease Cardiovascular & Haematological Disorders-Drug Targets, 2009; 9:1-8. PMID: 19275572.
  3. Seetharam RN, Sood A, Basu-Mallick A, Augenlicht LH, Mariadason JM, Goel S. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Res. 2010; (7):2531-8. PMID: 20682979.
  4. Sharma A, Heuck CJ, Fazzari MJ, Mehta J, Singhal S, Greally JM, Verma A. Wiley: DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer. Interdiscip Rev Syst Biol Med. 2010; 2(6):654-69. PMID: 20890963.
  5. Raghupathy R, Manwani D, Little JA. Review Article: Iron Overload in Sickle Cell Disease. Adv Hematol. 2010; 2010:272940. doi: 10.1155/2010/272940. Epub 2010 May 17. PMID: 20490352.
  6. Petrich A, Cho SI, Billett H. Primary cardiac lymphoma: an analysis of presentation, treatment, and outcome patterns. Cancer. 2011; 117(3):581-9. PMID: 20922788.
  7. Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kambhampati S, Parmar S, Nischal S, Hueck C, Suzuki M, Freidman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, McMahon C, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A. Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. Biol Chem. 2011; 286(28):25211-23. Epub 2011 Apr 30. PMID: 21532034.
  8. Zhou L, McMahon C, Bhagat T, Alencar C, Yu Y, Fazzari M, Sohal D, Heuck C, Gundabolu K, Ng C, Mo Y, Shen W, Wickrema A, Kong G, Friedman E, Sokol L, Mantzaris I, Pellagatti A, Boultwood J, Platanias LC, Steidl U, Yan L, Yingling JM, Lahn MM, List A, Bitzer M, Verma A. Reduced SMAD7 leads to over activation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase. Cancer Res. 2011; 71(3):955-63. Epub 2010 Dec 28. PMID: 21189329.
  9. Aparo S, Goel S. Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol. 2012; 83(1):47-58. doi: 10.1016/j.critrevonc.2011.08.006. Epub 2011 Sep 23. PMID: 21944740.
  10. Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012; 118(16):3977-83. doi: 10.1002/cncr.26723. Epub 2011 Dec 16. PMID: 22180164.
  11. Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, Braunchweig I, Barta S, Ghetie V, Vitetta E, Verma A. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol. 2011 Aug;154(4):471-6. doi: 10.1111/j.1365-2141.2011.08762.x. Epub 2011 Jul 7. PMID: 2173292.
  12. Dutta A, Karkashon S, Raghupathy R, Bhatia H, Tesfa L, Little JA. Induction of fetal/embryonic globin gene expression depends on intact cell signaling in definitive erythroid cells. Blood Cells Mol Dis. 2011; 46 (2):125-32. PMID: 21094617.
  13. Nayak J, Goel S. Revised TNM staging for colorectal cancer: did we miss the golden opportunity to do right by the staging? Clin Colorectal Cancer. 2011;10(3):207-9. Epub 2011 May 1. PMID: 21855045.
  14. Nayak J, Zhong Y, Haigentz M Jr: Acral metastases from laryngeal carcinoma. J Clin Oncol. 29: e220-1, 2011. PMID: 21189398.
  15. Abdullah, S. E. and Perez-Soler, R. (2011), Mechanisms of resistance to vascular endothelial growth factor blockade. Cancer. PMID: 22086782.
  16. Reed LR, Raghupathy R, Strakhan M, Philbeck TE, Kim MY, Battini B, Hussain Z, Abdullah S, Schweber S, Bala K. Pacello T. The OnControl bone marrow biopsy technique is superior to the standard manual technique for hematologists-in-training: a prospective, randomized comparison. Hematology Reports 2011; volume 3:e21 PMID: 22593813
  17. Janakiram M, Thirukonda VK, Sullivan M, Petrich AM. Emerging Therapeutic Targets in Diffuse Large B-Cell Lymphoma. Curr Treat Options Oncol. 2012;. [Epub ahead of print]. PMID: 22297843.
  18. Giricz O, Reynolds PA, Ramnauth A, Liu C, Wang T, Stead L, Childs G, Rohan T, Shapiro N, Fineberg S, Kenny PA, Loudig O. Hsa-miR-375 is differentially expressed during breast lobular neoplasia and promotes loss of mammary acinar polarity. J Pathol. 2012; 226(1):108-19. doi: 10.1002/path.2978. Epub 2011 Sep 26.
  19. Wang Y, Sparano JA, Fineberg S, Stead L, Sunkara J, Horwitz SB, McDaid HM. High Expression of Class III β-Tubulin Predicts Good Response to Neoadjuvant Taxane and Doxorubicin/Cyclophosphamide-Based Chemotherapy in Estrogen Receptor-Negative Breast Cancer. Clin Breast Cancer. 2012 Dec 5. PMID: 23218766.
  20. Mitotic counts in breast cancer after neoadjuvant systemic chemotherapy and development of metastatic disease. Diaz J, Stead L, Shapiro N, Newell R, Loudig O, Lo Y, Sparano J, Fineberg S. Breast Cancer Res Treat. 2013 Feb;138(1):91-7. doi: 10.1007/s10549-013-2411-7. Epub 2013 Feb 17. PMID: 23417359.
  21. Ayyappan S, Janakiram M, Raghupathy R. Current and emerging therapies in primary myelofibrosis. Cardiovasc Hematol Disord Drug Targets. 2012; 12(1):6-20. PMID: 22746348.
  22. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012; 120(2):386-94. Epub 2012 May 24. PMID:22627766.
  23. Abdullah SE, Haigentz M Jr, Piperdi B. Dermatologic Toxicities from Monoclonal Antibodies and Tyrosine Kinase Inhibitors against EGFR: Pathophysiology and Management. Chemother Res Pract. 2012; 2012:351210. Epub 2012 Sep 11 PMID: 22997576.
  24. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.Int J Clin Exp Pathol. 2012; 5(5):382-96. Epub 2012 May 23. PMID: 22808291.
  25. Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C, Tamari R, Yu Y, Bhagat TD, Bhattacharyya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A. Stem and progenitor cells in myelodysplastic syndromes show aberrant stage-specific expansion and harbor genetic and epigenetic alterations. Blood. 2012;120(10):2076-86. doi: 10.1182/blood-2011-12-399683. Epub 2012 Jul 2. PMID: 22753872.
  26. Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma. Clin Cancer Res. 2012;18(9):2534-44. PMID: 22338016.
  27. Janakiram M, Abadi YM, Sparano JA, Zang X. T cell coinhibition and immunotherapy in human breast cancer. Discov Med. 2012;14(77):229-36. PMID: 23114578.
  28. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer. 2012;11(2):143-50. Epub 2012 Jan 28. PMID: 22285706.
  29. Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, Reid EG, Aboulafia DM, Ratner L, Mitsuyasu R, Cooley T, Henry DH, Barr P, Noy A.Outcome of patients with relapsed/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999-2008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012; 53(12):2383-9. doi: 10.3109/10428194.2012.697559. Epub 2012 Jul 9. PMID: 22642936.
  30. Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012 12;120(2):386-94. Epub 2012 May 24. PMID: 22627766.
  31. Petrich AM, Sparano JA, Parekh S. Paradigms and Controversies in the Treatment of HIV-Related Burkitt Lymphoma. Adv Hematol. 2012; 10:765-6. PMID: 23271267.
  32. Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 118:3977-83, 2012. Epub 2011 Dec 16. PubMed PMID: 22180164.
  33. Sood A, McClain D, Maitra R, Basu-Mallick A, Seetharam R, Kaubisch A, Rajdev L, Mariadason JM, Tanaka K, Goel S. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Clin Colorectal Cancer. 2012; 11(2):143-50. Epub 2012 Jan 28. PMID: 22285706.
  34. Thirukonda V, Petrich A, Parekh S. Classical Hodgkin lymphoma and spontaneous regression. Clin Adv Hematol Oncol. 2012; 10(11):765-6. PMID: 23271267.
  35. Heuck CJ, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharyya S, Meagher R, Hu C, Maqbool S, Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A, Singhal SB. Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis. J Immunol. 2013;15;190(6):2966-75. doi: 10.4049/jimmunol.1202493. Epub 2013 Feb 13. PMID: 23408834.
  36. Bhagat TD, Zhou L, Sokol L, Kessel R, Caceres G, Gundabolu K, Tamari R, Gordon S, Mantzaris I, Jodlowski T, Yu Y, Jing X, Polineni R, Bhatia K, Pellagatti A, Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A. miR-21 mediates hematopoietic suppression in MDS by activating TGF-β signaling. Blood. 2013. [Epub ahead of print] PMID: 23390194.

Abstracts and Posters

  1. AP Lam, J Golubcow-Teglasi, K Gundabolu, H Ratech, KH Ramesh, LC Platanias, E Friedman, A Verma. High Prevalence of Elderly Anemia Is Seen in a Large Inner City outpatient Population and Is Predictive of Decreased Overall Survival across All Ethnic Groups ASH Annual Meeting Abstracts 2008 112:3447.
  2. L Zhou, JB Opalinska, DP Sohal, Y Mo, S Kambhampati, S Parmar, C Alencar, C Heuck, I Vigoda, C Ng, P Pahanish, S Goel, C Schinke, L Cytryn, E Friedman, Maria E Figueroa, AA Wickrema, J Greally, AVerma Integrative Genomic Analysis Reveals Aberrant Epigenetic Marks in MDS That Can Be Seen in Peripheral Blood Leucocytes ASH Annual Meeting Abstracts 2008 112:595.
  3. 4. L Zhou, AN Nguyen, D Sohal, JY Ma, P Pahanish, K Gundabolu, J Hayman, A Chubak, Y Mo, TD Bhagat, B Das, AM Kapoun, TA Navas, S Parmar, S Kambhampati, A Pellagatti, I Braunchweig, Y Zhang, A Wickrema, S Medicherla, J Boultwood, LC Platanias, LS Higgins, AF List, M Bitzer, A Verma. Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS Blood 2008 112:3434-3443; published ahead of print May 12, 2008, doi:10.1182/blood-2008-02-139824.
  4. DP Sohal, A Pellagati, L Zhou, Y Mo, JB Opalinska, C Alencar, C Heuck, A Wickrema, E Friedman, J Greally, BL Ebert, J Warner, J Boultwood, A Verma Downregulation of Ribosomal Proteins Is Seen in Non 5q- MDS ASH Annual Meeting Abstracts 2008 112:854.
  5. S Goel, C Schinke, T Bhagat, Y Mo, L Zhou, C Heuck, C Alencar, P Pahanish, J Anguiano, G Kabalka, LC Platanias, A Verma, B Das. Design and Synthesis of Novel Derivatives of ATRA Demonstrate the Combined Importance of Acid Moiety and Conjugated Double Bonds in Its Binding to PMLRAR-Alpha Oncogene in Acute Promyelocytic Leukemia ASH Annual Meeting Abstracts 2008 112:5036.
  6. L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M. Fazzari, DP Sohal, K Gundabolu, C Ng, Y Mo, A Wickrema, G Kong, E Friedman, L Sokol, PK Burnette, U Steidl, L Yan, J Yingling, MM Lahn, AF List, Ms Bitzer, A Verma Dysregulation of TGF-Beta Stimulated Smad Signaling Is Seen in Myelodysplasia and Points to the Potential Therapeutic Efficacy of TGF-Beta Receptor I Kinase Inhibition in Low Grade Disease. ASH Annual Meeting Abstracts 2009 114:737
  7. A. Basu Mallick, R. Seetharam, A. Sood, J. Mariadason, S. Goel; Evaluation of inducible expression of ERCC1 as a biomarker of drug response in human colorectal cancer cell lines. J Clin Oncol 28, 2010 (suppl; abstr e14048).
  8. A. Sood, D. McClain, R. Seetharam, M. Al-rahamneh, A. Kaubisch, L. Rajdev, K. Tanaka, J. Mariadason, S. Goel; Beyond KRAS: The quest for novel genetic markers predictive for response to anti-epidermal growth factor receptor (EGFR) therapy in patients with metastatic colorectal cancer (mCRC). J Clin Oncol 28:15s, 2010 (suppl; abstr 3567).
  9. V Leshchenko, Kuo P, Shaknovich R, Yang D, Gellen T, Petrich A, Yu Y, Remache Y, Weniger M, Rafiq S, Suh K, Goy A, Wilson W, Verma A, Braunschweig I, Muthusamy M, Kahl B, Byrd J, Wiestner A, Melnick A, Parekh S. Genome wide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma [Plenary Paper]. Blood, 2010; 116 (7): 1025-34.
  10. A Petrich, Leshchenko V, Kuo P, Ye BH, Sparano JA, Parekh S. Genomic and Pathway Connectivity Analyses Identify Novel Strategies to Overcome mTOR Inhibitor Resistance in DLBCL [abstract]. Oral presentation at ASH Annual Meeting, 2010 Dec 6; Orlando, FL.
  11. C. J. Heuck, J. Mehta, N. Pulliam, R. Meagher, L. Zhou, E. Vickrey, E. Voigt, J. Greally, A. Verma, S. Singhal; Multiple myeloma is characterized by widespread epigenomic alterations with prognostic implications. J Clin Oncol 28:15s, 2010 (suppl; abstr 8117).
  12. A Noy, Bayraktar UD, Gupta N, Petrich A, Moore P, Lensing S. Outcome of Patients with Relapsed/Refractory AIDS-Related Lymphoma In the AIDS Malignancy Consortium (AMC) 1997-2008 [abstract]. Poster presentation at ASH Annual Meeting, 2010 Dec 6; Orlando, FL.
  13. S Nischal, L Zhou, Y Yu, T Bhagat, Y Mo, C Heuck, M Suzuki, S Maqbool, A Pardanani, JGreally, A Moliterno, Averma. Epigenomic Profiling of Myeloproliferative Diseases Reveal Idiopathic Myelofibrosis as An Epigenetically Distinct Subgroup and Highlights the Epigenetic Effects of Jak2V617F Mutation ASH Annual Meeting Abstracts 2010 116:627.
  14. C Heuck, J Mehta, J Tariman, N Pulliam, Y Yu, T Bhagat, S Nischal, R Meagher, CY Hu, A Verma, SB Singhal. Epigenomic Profiling of Multiple Myeloma Shows Widespread Stage Specific Alterations In DNA Methylation That Occur Early During Myelomagenesis ASH Annual Meeting Abstracts 2010 116:784.
  15. A Petrich, Leshchenko, V, Kuo P, Sparano JA, Parekh S. Targeting the mTOR/AKT pathway with Nelfinavir: Implications for AIDS-related Lymphomas [abstract]. Poster presentation at NYCC Developmental Therapeutics Symposium, 2010 May 14; New York, NY.
  16. A. Sood, D. McClain, A. Kaubisch, L. Rajdev, J. Mariadason, K. Tanaka, S. Goel. Use of PTEN expression in the primary tumor as a predictive marker for radiologic response to anti-epidermal growth factor receptor (EGFR) based therapy in patients with metastatic colorectal cancer (mCRC). 2010 Gastrointestinal Cancers Symposium. Orlando, FL.
  17. J Chuy, Kinkhabwala M, Reinus J, Tanaka K, Kaubisch A. Bridging therapy for hepatocellular carcinoma prior to orthotopic liver transplantation results in disease control but few complete responses. 2011 Gastrointestinal Cancers Symposium, San Francisco, CA. January 20-22, 2011.
  18. J Chuy, Moadel A, Haynes H, Garg M, Schiff BA, Smith RV, Sarta C, Eng Y, Schlecht N, Negassa A, Haigentz M. Clinical and behavioral characteristics of active smokers with squamous cell carcinoma of the head and neck (SCCHN) in an urban setting: Attitudes underlying high-risk disease. 2011 ASCO Annual Meeting, June 4-8 2011; Chicago, IL. Abstract e16027.
  19. JB Nayak, R. Maitra, A. Basu-Mallick, A. Sood, J. Mariadason, D. M. Reynolds, S. Goel; High throughput sequencing technology (Sequenom) as a tool to detect SNPs in human metastatic colorectal cancer (mCRC) and cell lines. J Clin Oncol 29: 2011 (suppl; abstr e14083).
  20. LA Stead, A. Ramnauth, S. Fineberg, O. Loudig; MicroRNA expression patterns in lobular neoplasia. Clin Oncol 29: 2011 (suppl; abstr 10551).
  21. CM Schinke, B C Das, S Goel, T Bhaga, S Nischa, S Minucci, G Kabalka, RE Gallagher, T Evans, LC Platanias, A Verma. Design, Synthesis and Biological Evaluation of A Boron Containing Retinoid As a Novel Therapeutic Agent for Acute Promyelocytic Leukemia. ASH Annual Meeting Abstracts 2011 118:5008.
  22. TD Bhagat, L Zhou, L Sokol, I Mantzaris, K Gundabolu, SAK Gordon, Y Yu, S Nischal, R Polineni, C Schinke, G Chrysofakis, A Wickrema, A Pellagatti, J Boultwood, UI Steidl, G Liu, AlF List, M Bitzer, A Verma. Mir-21 Mediates Hematopoietic Suppression in MDS by Activating TGF-b Signaling, ASH Annual Meeting Abstracts 2011 118:3813.
  23. SK Barta, Y Zou, J Schindler, T Bhagat, V Ghetie, ES Vitetta, A Verma. Synergy of Sequential and Concurrent Administration of a Deglycosylated Ricin A Chain-Containing Combined Anti-CD19 and Anti-CD22 Immunotoxin (Combotox) and Cytarabine in a Murine Model of Advanced Acute Lymphoblastic Leukemia ASH Annual Meeting Abstracts 2011 118:1526.
  24. R Tamari, HH Billett, H Cohen D-Dimer Variability in the Postpartum Period, ASH Annual Meeting Abstracts 2011 118:3337.
  25. S Maingi, S O’Mahony, J Siegel, End-of-Life Challenges for a Transgender Patient at The World Professional Association for Transgender Health (WPATH) 22nd WPATH Biennial Symposium, 2011, Atlanta, GA.
  26. S. Maingi, S. O'Mahony. Transgender Patients in Palliative Care Settings. Oral Presentation at the National Transgender Health Summit, San Francisco, CA, April 8 – 9, 2011.
  27. LJ Reed, R Raghupathy, M Strakhan, T Philbeck, MY Kim, R Battini, Z Hussain, S Abdullah, S Schweber, K Bala, T Pacello. The Powered Bone Marrow Biopsy Technique Is Superior to the Standard Manual Technique for Hematologists-In-Training: A Prospective, Randomized Comparison. Blood (ASH Annual Meeting Abstracts), Nov 2011; 118: 3133.
  28. Janakiram, M, Sullivan, MR, Shcherba, M, Guo, M. and Billett, HH. Residual Vein Residual Vein Obstruction (RVO) Predicts Recurrence for Cancer Patients with Secondary VTE: A Meta-Analysis. Abstract 2259. American Society of Hematology, 54th Annual Meeting, December 2012.
  29. U Swami, MH Ghalib, I Chaudhary, JY Hou, S. Aparo, MH Einstein, GL Goldberg, T Elrafei, S Gajavelli, B Cohen, L Rajdev, A Kaubisch, M Haigentz, S Mani, S Goel. Risks and benefits of phase I trials: Twelve-year experience from a single institution. ASCO 2011 (abstr 6098).
  30. M Mita, S Aparo, Y Wang, J Sarantopoulos, GS Vemulapalli, A Mita, S Goel, A Kaubisch, M Coffey, G Gill, D Mahalingam. A phase I/II Study of REOLYSIN in Combination with Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma. AACR-EORTC (abstr B55).
  31. A Merla, A Basu Mallick, T Augustine, I Chaudhary, S Gajavelli, R Maitra, C Daroqui, S Aparo, R Seetharam, L Rajdev, A Kaubisch, S Madajewicz, A Negassa, J Mariadason, M Ghalib, S Goel. The kinetics of the excision repair cross-complementing group-1 (ERCC1) gene in patients with colorectal cancer. ASCO 2012 (abstr e14019).
  32. SK. Barta, X Xue, R Tamari, JY Lee, NM, Lawrence D. Kaplan, J-M Ribera, M Spina, R Weiss, L Galicier, F Boue, WH Wilson, C Wyen, JT Navarro, K Dunleavy, RF Little, L Ratner, M Morgades, O Garcia, JA Sparano; A pooled analysis of 1144 patiennts wit HIV associated lymphoma: Assesment of lymphoma, HIV, and treatment spesific factors on clinical outcomes. J Clin Oncol 30, 2012 (suppl; abstr 8005).
  33. R. Maitra, JB Nayak, A Basu-Mallick, A Sood, TA Augustine, J Mariadason, DM Reynolds, S Goel. Rapid screening of SNPs in metastatic colorectal cancer (mCRC) utilizing multiplex sequencing technology (Sequenom). J Clin Oncol 30, 2012 (suppl 4; abstr 418).
  34. MA Baig, A Merla, TA Augustine, G Atzmon, T Budagov, S Goel, R Maitra. Association of telomere length (TL) with clinical outcomes in patients with colorectal carcinoma (CRC). J Clin Oncol 30: 2012 (suppl 34; abstr 418)
  35. AP Lam, K Gundabolu, A Sridharan, R Jain, P Msaouel, G Chrysofakis, Y Yu, E Friedman, E Price, SL Schrier, A Verma. Multiplicative Interaction Between Mean Corpuscular Volume and Red Cell Distribution Width in Predicting Mortality of Elderly Patients with and without Anemia ASH Annual Meeting Abstracts 2012 120:5150.
  36. S Sundaravel, TD Bhagat, C Schinke, D Ebenezer, H Liu, Y Yu, A Pellagatti, J Boultwood, V Yajnik, A Artz, A Verma, A Wickrema. Aberrant Expression of DOCK4 Leads to Disruption of the F-Actin Skeleton and Altered Membrane Stability in MDS Erythroblasts and Mature Erythrocytes. ASH Annual Meeting Abstracts 2012 120:924.
  37. P Msaouel, AP Lam, K Gundabolu, G Chrysofakis G, Y Yu, EW Friedman, A Verma. The Independent Effect of Platelet Count On Mortality in a Large Inner City Elderly Outpatient Population. ASH Annual Meeting Abstracts 2012 120:4645.
  38. M Janakiram, MR Sullivan, M Shcherba, S Guo, HH Billett. Residual Vein Obstruction (RVO) Predicts Recurrence for Cancer Patients with Secondary VTE: A Meta-Analysis. ASH Annual Meeting Abstracts 2012 120:2259
  39. Jain R, A Shridharan A, Y Yu, KH Ramesh, K Gundabolu, Friedman E, A Verma. Epidemiological study of myelodysplastic syndrome in racially diverse inner-city population. J Clin Oncol 31, 2013 (suppl; abstr 7125).
  40. M. Shcherba, S Viswanathan, D Blakaj, M Garg, M Haigentz. Treatment-associated mortality in head and neck cancer: Analysis of phase III trials. J Clin Oncol 31, 2013 (suppl; abstr 6064).
  41. S. Schweber, AG. Rodriguez-LaRocca, V. Calvert, E. Petricoin, SB. Horwitz, E. Andreopoulou, HM. McDaid. Protein pathway activation mapping guided biomarker development to identify optimal combinations of MEK inhibitor with PI3K/mTOR pathway inhibitors for the treatment of triple-negative breast cancer. J Clin Oncol 31, 2013 (suppl; abstr 2612).
  42. U. Shah, G. Pendurti, U. Swami, Y. Hou, MH. Ghalib, I. Chaudhary, S. Mani, S. Goel, S. Aparo. Clinical outcome for patients with metastatic colorectal cancer (mCRC) enrolled in phase I clinical trials: Single institution experience. J Clin Oncol 31, 2013 (suppl; abstr e13550).
  43. E. Andreopoulou, IS. Vigoda, V. Valero, DL. Hershman, G. Raptis, LT. Vahdat, HS. Han, JJ. Wright, CM. Pellegrino, RH. Alvarez, K. Fehn, S. Fineberg, JA. Sparano; A phase I-II study of tipifarnib plus weekly paclitaxel (P) followed by dose-dense doxorubicin/cyclophosphamide (AC) in stage IIb-IIIc breast cancer (BC). J Clin Oncol 31, 2013 (suppl; abstr 1118).
  44. SK. Barta, M. Samuel, X. Xue, JY. Lee, N. Mounier, LD. Kaplan, JM. Ribera, M. Spina, U. Tirelli, R. Weiss, L. Galicier, F. Boue, WH. Wilson, C. Wyen, K. Dunleavy, RF. Little, SC. Remick, M. Goldfinger, A. Noy, J A. Sparano: A pooled analysis of 1,546 patients with AIDS-related lymphoma (ARL): An assessment of prognostic factors by treatment era. J Clin Oncol 31, 2013 (suppl; abstr 8524).
  45. MA. Baig, TA. Augustine, A. Merla, G. Atzmon, T. Budagov, S. Goel, R. Maitra; Association of telomere length with clinical outcomes in patients with colorectal carcinoma. J Clin Oncol 31, 2013 (suppl; abstr e14540).